What a 'hyperplastic polyp' means on your colonoscopy report

Take the phrase apart. A polyp is any small growth rising from the lining of the colon; it is a shape word, not a diagnosis. 'Hyperplastic' is built from hyper (extra) and plasia (growth or formation): the cells of the lining made a few more of themselves than usual and stacked into a small mound. Under the microscope, the tiny glands inside it take on a saw-toothed outline, which is why pathologists file it in the 'serrated' family. Your report may add a subtype word like 'microvesicular' or 'goblet cell-rich'; those describe which lining cells did the overgrowing, and neither changes the diagnosis or the follow-up. Crucially, the cells themselves look normal. There are just more of them than the lining strictly needs.

That is what separates this finding from the polyps that earn the word 'precancerous.' An adenoma is defined by dysplasia, cells that look abnormal under the microscope. A hyperplastic polyp is defined by the absence of it: ordinary cells, in a slightly overgrown arrangement. Your report may even say so outright, in the line 'negative for dysplasia,' which step 4 decodes.

And here is the fact the report never states, because to the two doctors reading it, it goes without saying: polyps found during a colonoscopy are removed during the colonoscopy. The pathology report exists because the removal already happened. Whatever this report describes is in a jar at the lab, not in you. For most small hyperplastic polyps, the entire life of the finding is: seen, removed in seconds, named a week later, never thought about again.

In 2020, the US Multi-Society Task Force on Colorectal Cancer, the group whose recommendations set most American follow-up schedules, reviewed the evidence on small hyperplastic polyps in the rectum and sigmoid colon and wrote this: patients with them appear to have 'a similar risk of metachronous advanced neoplasia as patients with a normal examination' (Gupta and colleagues, 2020). Translated: the risk of something serious turning up at the next exam looks the same as if the colonoscopy had found nothing. The British guideline says the same thing more bluntly: diminutive (tiny) rectosigmoid hyperplastic polyps 'are not thought to be risk markers for future CRC risk' (British Society of Gastroenterology, 2017).

Hold that against how common the finding is. Serrated-family polyps, most of them hyperplastic, turn up in roughly 20 to 40 percent of average-risk adults who get a screening colonoscopy, and hyperplastic polyps alone account for about a quarter to two fifths of all polyps removed (Crockett and Nagtegaal, Gastroenterology, 2019; BSG, 2017). If a screening colonoscopy were a lottery, this is one of the most ordinary tickets it prints.

One more anchor while the numbers are out. The average American's lifetime risk of colorectal cancer is about 3.9 percent, roughly 1 in 25 (SEER, 2021 to 2023 data). A small rectal or sigmoid hyperplastic polyp does not move that number, which is the practical meaning of 'similar risk as a normal examination.' The finding earns a line in the report and, for the usual case, nothing else: no medicine, no scan, no earlier appointment.

Colon polyps split into two big branches. The adenoma branch (tubular, tubulovillous, villous) is the classic precancerous kind: removed, then watched on a schedule, the whole subject of the tubular adenoma guide. The serrated branch, named for that saw-toothed outline, splits again, and this split is the one your report vocabulary comes from. The World Health Organization sorts it into three: the hyperplastic polyp, the sessile serrated lesion (also written SSL, or 'sessile serrated adenoma/polyp' on older reports), and the rare traditional serrated adenoma. The last two are precancerous. The hyperplastic polyp is not (Crockett and Nagtegaal, 2019).

This is why searching 'serrated polyp' from a report that says 'hyperplastic' is such a reliable way to scare yourself. The scary statistics you will find, like the estimate that this pathway accounts for 15 to 30 percent of colorectal cancers (BSG, 2017), belong to the sessile serrated lesion's branch of the tree, not yours. Some health sites drop that statistic into their hyperplastic polyp articles without drawing the line between the two. The line is the whole point.

The diagnosis line, not the adjectives, tells you which one you have. 'Hyperplastic polyp' means the benign one, even when the surrounding text says 'serrated architecture' or files it as a 'serrated polyp, hyperplastic type.' 'Sessile serrated lesion,' 'sessile serrated polyp,' or 'sessile serrated adenoma' means the precancerous one, which is still a removed, slow, watched-on-a-schedule finding, not a cancer diagnosis.

And note one trap: 'sessile' by itself is just a shape word meaning flat and broad-based (its opposite, 'pedunculated,' means on a stalk; both are shape words). A procedure note saying 'the polyp was sessile' has told you how it sat, not what it was. Only the pathologist's phrase 'sessile serrated' names the other diagnosis.

A colonoscopy pathology report has a fixed anatomy, covered in full in the pathology report guide: a specimen line, a description, and a diagnosis. Read the diagnosis first. For this finding it often looks like this real example: 'Rectum: colorectal mucosa: hyperplastic polyp/s. Negative for dysplasia and malignancy.' Everything else on the page is process.

The specimen and procedure lines describe logistics, not severity. 'Polypectomy' means polyp removal. 'Cold biopsy forceps' or 'cold snare' name the standard tool for small polyps ('cold' means no cauterizing current was needed, which is typical for something this size). The location word (cecum, ascending, transverse, sigmoid, rectum) matters here more than it does for adenomas, for one reason step 6 explains: right-sided serrated polyps get a closer look than rectal ones.

'Fragments' and 'in aggregate' are the phrases that generate the most midnight searches, and both describe how tissue arrived at the lab. A small polyp removed with forceps often arrives in a few pieces, so the pathologist writes 'multiple irregular fragments of tan-pink soft tissue measuring 0.5 x 0.5 cm in aggregate,' meaning: pieces, measured together. It is a description of the jar's contents, not a comment on danger. The same goes for stray extra lines, like a note about debris or reactive cells: the pathologist names everything the forceps picked up, because naming everything is the job.

Then the verdict, often in capitals: 'NEGATIVE FOR DYSPLASIA AND MALIGNANCY.' People read the words 'dysplasia' and 'malignancy,' feel their stomach drop, and miss the 'negative for' in front. That line is the pathologist affirmatively saying the two things worth ruling out were both looked for and both absent. For a hyperplastic polyp it is close to a formality (no dysplasia is what makes it hyperplastic), but the report states it anyway, because the report is the permanent record.

And if your portal stamps the whole result with an 'abnormal' flag, know what that flag measures: anything that is not literally normal tissue gets it. A benign polyp is 'abnormal' in that dialect. One patient described dreading her follow-up for a week over that word; the finding underneath it was this one. If the report ends by recommending clinical correlation, that is routine hand-back language, decoded in its own guide.

Your next-colonoscopy date comes from a published table, and for hyperplastic polyps the 2020 US Multi-Society Task Force table has three rows (Gupta and colleagues, Gastroenterology, 2020). Up to twenty hyperplastic polyps under 10 millimeters in the rectum or sigmoid: back to routine screening in ten years, the guideline's strongest recommendation in this section. The same small polyps proximal to the sigmoid (further in, toward the right side): ten years again, though the task force labels the evidence weaker there. Any hyperplastic polyp 10 millimeters or larger: back in three to five years, with three favored when there is doubt about the pathology reading, the bowel prep, or whether the polyp came out completely.

Notice what is not in that table: five years for a small rectal polyp, or a shorter leash just because something was found. Ten years after a small rectosigmoid hyperplastic polyp is not your doctor rounding up from generosity. It is the same interval a completely clean exam earns, which is the guideline acting out the sentence from step 2.

If your letter names a different number, there is usually a reason worth one question rather than a weekend of searching. The most common: the exam found other things too, and the schedule keys off the most advanced finding, so an adenoma elsewhere in the colon sets the date and the hyperplastic line is just along for the ride. Also common: the polyp was proximal or large (the other rows of the table), the prep was graded less than adequate, or the practice is still using an older table. 'Which finding set my interval?' is a fair, answerable question for the follow-up call, and the questions guide has the longer list.

Here is the part no patient page on the first page of Google explains: telling a hyperplastic polyp from a sessile serrated lesion under the microscope is genuinely hard, and pathologists themselves agree only moderately. In one study, five pathologists reviewing 185 serrated polyps reached only 'moderate' agreement (a kappa statistic of 0.55, where 1.0 is perfect), and it barely improved when they tried again with refined criteria (Farris and colleagues, American Journal of Surgical Pathology, 2008). A 2021 exercise with eight experienced GI pathologists found the same: agreement of 0.55 for hyperplastic polyps and 0.44 for sessile serrated lesions (Vennelaganti and colleagues, Gastroenterology). These are specialists, disagreeing with each other about the exact distinction your follow-up interval depends on.

The guideline writers know this, and wrote the uncertainty into the schedule. For small hyperplastic polyps on the right side of the colon, where sessile serrated lesions concentrate and the two look most alike, the task force explicitly allows clinicians who doubt the local distinction to just use the sessile-serrated schedule instead (Gupta and colleagues, 2020). So when a nurse says 'come back in three years' and your own search of the guideline says ten, you are usually not looking at an error. You are looking at a doctor pricing in the location of your polyp, its size, or the known fuzziness of the diagnosis. A report line like 'cannot exclude sessile serrated lesion' is the pathologist doing the same thing out loud.

The same fuzziness explains a failure mode families hit in the portal: a templated message that contradicts the report. One patient's pathology said hyperplastic polyp; the doctor's portal message called it a precancerous adenoma. The likely explanation, spotted by another reader, was mundane: the doctor filled in a return interval and the system attached its stock adenoma paragraph. When a message and a pathology report disagree, the pathology report is the record. The polite, useful version of that sentence for the portal is: 'My results message says adenoma, but the pathology report says hyperplastic polyp with no dysplasia. Can you confirm which one my follow-up interval is based on?'

If you searched this term, you probably met the contradiction: a major clinic saying hyperplastic polyps do not become cancer, and a 2004 research abstract, still ranking, arguing they are 'not harmless.' Both were right when written, because they are not describing the same category. Until the early 2000s, 'hyperplastic polyp' was a bucket that also held the flat, subtle, right-sided polyps now called sessile serrated lesions. Pathologists had noticed the problem as early as 1996, when Torlakovic and Snover described patients whose 'hyperplastic' polyposis behaved like a precancerous disease; their 2003 follow-up drew the line under the microscope that split the category in two. The risky polyps got a new name and their own schedule. The name 'hyperplastic polyp' kept the harmless remainder.

That renaming is why publication dates matter more than usual in this corner of the internet, and why a parent's colonoscopy report from 2005 saying 'hyperplastic polyp' cannot be compared line for line with yours. It is also why the old worry that a rectal hyperplastic polyp signals trouble deeper in the colon faded: a 2005 meta-analysis found the apparent link disappeared in the high-quality screening studies, and concluded that finding one 'should not automatically prompt' a deeper hunt (Lin and colleagues, Archives of Internal Medicine, 2005).

The modern era runs the other direction: doctors are now graded partly on how well they find serrated polyps, because the subtle ones (the sessile serrated lesions) hide in the colon's right side. The 2024 US quality targets ask colonoscopists to find precancerous polyps in at least 35 percent of screening exams and sessile serrated lesions in at least 6 percent (Rex and colleagues, American Journal of Gastroenterology, 2024). A Dutch study of 277,555 colonoscopies found that every percentage-point increase in an endoscopist's detection rate for serrated polyps in the proximal (right side of the) colon came with a 7 percent drop in their patients' risk of a cancer appearing before the next exam (van Toledo and colleagues, Lancet Gastroenterology and Hepatology, 2022). Read your report in that light: an exam that found and named a small serrated-family polyp is an exam that was looking carefully.

Size is the first. A hyperplastic polyp of 10 millimeters (one centimeter) or more moves you to the three-to-five-year row of the table, partly because large serrated polyps are harder to remove completely: in the study that measured it, incomplete resection was found in 31 percent of sessile serrated polyps versus about 7 percent of conventional adenomas among mid-sized flat polyps (Pohl and colleagues, Gastroenterology, 2013). If your report pairs a large polyp with margin language, the earlier recheck is the system making sure the site is clean, not a suspicion of cancer.

Count is the second, and the bar is high. Serrated polyposis syndrome, the condition where serrated polyps come in real numbers, is diagnosed only at thresholds like five serrated polyps beyond the rectum all 5 millimeters or larger (at least two of them 10 millimeters or larger), or more than twenty throughout the colon (WHO criteria; Dekker and colleagues, Gastroenterology, 2020). It is rare, on the order of 1 in 2,000 to 1 in 7,000 screening colonoscopies, and it is taken seriously because cancer risk is genuinely elevated; the reassuring half of the same literature is that under annual surveillance that risk falls to about 2 cancers per 1,000 person-years (IJspeert and colleagues, Gut, 2017). One or two small hyperplastic polyps do not put you anywhere near this diagnosis.

Location off the colon is the third. A hyperplastic polyp in the stomach, found on an endoscopy rather than a colonoscopy, is a different entity that happens to share the name: it grows in response to chronic irritation (often H. pylori infection or atrophic gastritis), it can shrink after the underlying irritation is treated, and larger ones carry a small but real risk of harboring worse, which is why stomach ones over a centimeter get removed and followed differently (StatPearls). If you are reading an upper-endoscopy report, this guide's reassurance math does not transfer; the name does.

And the family question, because someone at the dinner table will ask. The guidelines that move a relative's screening earlier key off colorectal cancer or advanced precancerous polyps in a close relative. A hyperplastic polyp is neither, and the major screening guidelines do not move a family member's start date because of one. What actually sets your family's schedule is the family history itself, which is a good reason to keep everyone's reports findable in one place rather than reconstructed from memory: the difference between 'Dad had a precancerous polyp at 55' and 'Dad had a hyperplastic polyp at 55' is, as this guide has spent eight steps showing, the whole ballgame.